Effects of Tirzepatide, a Dual GIP and GLP-1 RA, on Lipid and Metabolite Profiles in Subjects With Type 2 Diabetes

• Published in: The journal of clinical endocrinology and metabolism Vol. 107; no. 2; pp. 363 - 378
• Main Authors: Pirro, Valentina, Roth, Kenneth D, Lin, Yanzhu, Willency, Jill A, Milligan, Paul L, Wilson, Jonathan M, Ruotolo, Giacomo, Haupt, Axel, Newgard, Christopher B, Duffin, Kevin L
• Format: Journal Article
• Language: English
• Published: US Oxford University Press 01.02.2022
• Subjects: Adult; Aged; Beta cells; Blood Glucose - analysis; Blood Glucose - metabolism; Body weight; Body weight loss; Branched chain amino acids; Comparative analysis; Dextrose; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - blood; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - metabolism; Diabetes therapy; Diglycerides; Female; Gastric Inhibitory Polypeptide - administration & dosage; Gastric Inhibitory Polypeptide - adverse effects; Gastric Inhibitory Polypeptide - metabolism; Glucagon; Glucagon-like peptide 1; Glucagon-Like Peptide 1 - metabolism; Glucagon-Like Peptide-1 Receptor - agonists; Glucagon-Like Peptide-1 Receptor - metabolism; Glucagon-Like Peptides - administration & dosage; Glucagon-Like Peptides - adverse effects; Glucagon-Like Peptides - analogs & derivatives; Glucose; Glucose metabolism; Glutamate; Glycated Hemoglobin A - analysis; Glycosylated hemoglobin; Hemoglobin; Humans; Hypoglycemic Agents - administration & dosage; Hypoglycemic Agents - adverse effects; Immunoglobulin Fc Fragments - administration & dosage; Immunoglobulin Fc Fragments - adverse effects; Injections, Subcutaneous; Insulin; Insulin resistance; International economic relations; Lipid metabolism; Male; Metabolism; Metabolites; Metabolomics; Middle Aged; Peptides; Pharmaceutical industry; Physiological aspects; Placebos; Receptors, Gastrointestinal Hormone - agonists; Receptors, Gastrointestinal Hormone - metabolism; Recombinant Fusion Proteins - administration & dosage; Recombinant Fusion Proteins - adverse effects; Triglycerides; Triglycerides - blood; Triglycerides - metabolism; Type 2 diabetes; Weight Loss - drug effects; Young Adult; United States; diabetes; glucose metabolism; insulin signaling
• ISSN: 0021-972X; 1945-7197; 1945-7197
• DOI: 10.1210/clinem/dgab722

Abstract Context Tirzepatide substantially reduced hemoglobin A1c (HbA1c) and body weight in subjects with type 2 diabetes (T2D) compared with the glucagon-like peptide 1 receptor agonist dulaglutide. Improved glycemic control was associated with lower circulating triglycerides and lipoprotein markers and improved markers of beta-cell function and insulin resistance (IR), effects only partially attributable to weight loss. Objective Assess plasma metabolome changes mediated by tirzepatide. Design Phase 2b trial participants were randomly assigned to receive weekly subcutaneous tirzepatide, dulaglutide, or placebo for 26 weeks. Post hoc exploratory metabolomics and lipidomics analyses were performed. Setting Post hoc analysis. Participants 259 subjects with T2D. Intervention(s) Tirzepatide (1, 5, 10, 15 mg), dulaglutide (1.5 mg), or placebo. Main Outcome Measure(s) Changes in metabolite levels in response to tirzepatide were assessed against baseline levels, dulaglutide, and placebo using multiplicity correction. Results At 26 weeks, a higher dose tirzepatide modulated a cluster of metabolites and lipids associated with IR, obesity, and future T2D risk. Branched-chain amino acids, direct catabolic products glutamate, 3-hydroxyisobutyrate, branched-chain ketoacids, and indirect byproducts such as 2-hydroxybutyrate decreased compared to baseline and placebo. Changes were significantly larger with tirzepatide compared with dulaglutide and directly proportional to reductions of HbA1c, homeostatic model assessment 2-IR indices, and proinsulin levels. Proportional to metabolite changes, triglycerides and diglycerides were lowered significantly compared to baseline, dulaglutide, and placebo, with a bias toward shorter and highly saturated species. Conclusions Tirzepatide reduces body weight and improves glycemic control and uniquely modulates metabolites associated with T2D risk and metabolic dysregulation in a direction consistent with improved metabolic health.